Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 16.2005
- Book/Share 7.9596
- PB 5.3968
- Debt/Equity 1.082
- CurrentRatio 0.8186
- ROIC 0.1551
- MktCap 88559524037.991
- FreeCF/Share 3.1029
- PFCF 14.2029
- PE 15.4575
- Debt/Assets 0.2899
- DivYield 0.0297
- ROE 0.2979
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GSK | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | GSK | Barclays | Equal Weight | Underweight | -- | -- | Jan. 6, 2026 |
| Upgrade | GSK | BofA Securities | Underperform | Neutral | -- | -- | Nov. 25, 2025 |
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In GSK To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered losses exceeding $75,000 in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GSK …
Read More
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140758&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Deadline: Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: April 03, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022. GSK is a “global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegatio.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
GSK Investors Have Opportunity to Lead GSK plc Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
Read More
Shareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Shareholders that lost money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140552&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – GSK
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline.
Read More
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to GSK plc.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders that lost money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140450&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2025.
Read More
Levi & Korsinsky Notifies Shareholders of GSK plc(GSK) of a Class Action Lawsuit and an Upcoming Deadline
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140248&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140197&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
GSK DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Why GSK (GSK) is a Top Value Stock for the Long-Term
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140036&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=139546&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
Read More
GSK plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - GSK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=139176&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
GSK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GSK plc Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=139017&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Luke Victor Miels
- Employees 68629